EAM

Exome Asset Management Portfolio holdings

AUM $202M
1-Year Est. Return 151.75%
This Fund
S&P 500
This Quarter Est. Return
1 Year Est. Return
+151.75%
3 Year Est. Return
5 Year Est. Return
10 Year Est. Return
AUM
$151M
AUM Growth
+$41.1M
Cap. Flow
Cap. Flow %
Top 10 Hldgs %
Holding
85
New
Increased
Reduced
Closed

Top Buys

1
+$9.28M
2
+$4.89M
3
+$3.6M
4
CVS icon
CVS Health
CVS
+$2.99M
5
AKRO
Akero Therapeutics
AKRO
+$2.84M

Top Sells

1
+$2.99M
2
+$2.5M
3
+$2.49M
4
VSTM icon
Verastem
VSTM
+$2.49M
5
GERN icon
Geron
GERN
+$2.07M

Sector Composition

1 Healthcare 97.76%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VTYX
51
DELISTED
Ventyx Biosciences
VTYX
$188K 0.12%
+60,600
IMUX icon
52
Immunic
IMUX
$148M
$153K 0.1%
+173,900
RGNX icon
53
Regenxbio
RGNX
$438M
– –
-226,060
KPTI icon
54
Karyopharm Therapeutics
KPTI
$161M
– –
0
APLS icon
55
Apellis Pharmaceuticals
APLS
$2.57B
– –
-98,600
ACAD icon
56
Acadia Pharmaceuticals
ACAD
$3.78B
– –
0
ALT icon
57
Altimmune
ALT
$443M
– –
0
ALVO icon
58
Alvotech
ALVO
$1.25B
– –
-78,372
ANAB icon
59
AnaptysBio
ANAB
$1.53B
– –
-15,000
ARCT icon
60
Arcturus Therapeutics
ARCT
$202M
– –
0
BCRX icon
61
BioCryst Pharmaceuticals
BCRX
$2.13B
– –
-172,883
CLDX icon
62
Celldex Therapeutics
CLDX
$1.96B
– –
-73,000
CMPS
63
Compass Pathways
CMPS
$747M
– –
-213,544
CRNX icon
64
Crinetics Pharmaceuticals
CRNX
$4B
– –
-62,700
DYN icon
65
Dyne Therapeutics
DYN
$2.45B
– –
-195,933
ELDN icon
66
Eledon Pharmaceuticals
ELDN
$221M
– –
-114,145
ELEV
67
DELISTED
Elevation Oncology
ELEV
– –
-110,353
GPCR icon
68
Structure Therapeutics
GPCR
$4.09B
– –
-53,744
LEGN icon
69
Legend Biotech
LEGN
$3.5B
– –
-29,100
MREO
70
Mereo BioPharma
MREO
$62.7M
– –
0
NAMS icon
71
NewAmsterdam Pharma
NAMS
$3.43B
– –
-36,574
NKTR icon
72
Nektar Therapeutics
NKTR
$1.98B
– –
0
NVO icon
73
Novo Nordisk
NVO
$171B
– –
0
OEF icon
74
iShares S&P 100 ETF
OEF
$28.2B
– –
0
PGEN icon
75
Precigen
PGEN
$1.17B
– –
0
1 2
3
4